Ali Ahmed, senior vice president of biosimilars for Fresenius Kabi USA discusses FDA review of the company’s Stimufend pegfilgrastim biosimilar candidate and the marketing of this product.
In this interview, The Center for Biosimilars® speaks with Ali Ahmed, senior vice president of Biosimilars for Fresenius Kabi USA. Ahmed talks about the prospects for the company’s pegfilgrastim biosimilar candidate (Stimufend, referencing Amgen’s Neulasta).
He also discusses Fresenius Kabi’s planned tocilizumab biosimilar candidate (MSB11456), for which positive results were recently reported. MSB11456, for the treatment of rheumatoid arthritis, would reference Actemra.
The company is awaiting completion of an FDA site inspection to enable the completion of the Stimufend application review. Backlogs at the FDA largely owing to COVID-19 have slowed the process for many manufacturers. “We do know that there’s a shortage of resources and they’re doing the best they can under the circumstances,” Ahmed says. The company is cautiously optimistic about an approval in the near future.
For Fresenius Kabi, launching Stimufend would represent the launch of the company’s biosimilars business and an opportunity to extend Fresenius Kabi’s oncology business in the United States. “We have a very robust portfolio with something on the order of 34 different chemotherapy agents currently on the market,” Ahmed says.
The market for pegfilgrastim products is competitive and prices have declined significantly since the first biosimilars appeared. Ahmed says that Fresenius Kabi hopes to compete by differentiating Stimufend via strong customer relationships and patient support, rather than a lowest-cost strategy.
The company has sized up the European Union market for pegfilgrastim biosimilars, and Ahmed notes a chief difference there vs in the United States is that Amgen’s successful Onpro wearable pegfilgrastim device is not available in Europe currently. This product has a roughly 50% share of the market in the United States, and so the competitive dynamics are very different on one side of the Atlantic vs the other. Ultimately, though, Fresenius Kabi does hope to bring a wearable injector to market, Ahmed says.
When it comes to bringing a tocilizumab product to the US market, Fresenius Kabi could be the first, Ahmed notes.
Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings
May 16th 2024Two posters from the Academy of Managed Care Pharmacy’s annual meeting provided hope that despite low uptake so far, adalimumab biosimilars can deliver on the promise of comparable safety and efficacy with the originator in multiple disease states, as well as cost savings.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches
May 14th 2024The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Cordavis Report Outlines Strategies for Biosimilar Development, Access in the US Health Care Market
May 8th 2024Cordavis, a CVS Healthspire company, released a report detailing the current hurdles faced in developing and commercializing biosimilars in the US and highlighting efforts by the organization to enhance access and affordability for these products.